Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one
 dose of four different formulations of the MenACWY conjugate vaccine when given to healthy
 subjects aged 15-19 years. The selection of the best formulation will be based on data
 obtained up to one month after the vaccine dose.
The study is open. However, the 4 different formulations of GSK's MenACWY conjugate vaccine
 will be administered in a double-blind manner. Mencevax™ ACWY vaccine will serve as active
 control. Subjects will receive one vaccine dose only (GSK's MenACWY conjugate vaccine or
 Mencevax™ ACWY vaccine), and will have 2 blood samples taken, before and one month after
 vaccination.
Inclusion Criteria:

 -  Healthy male or female between, and including, 15 and 19 years of age at the time of
 vaccination.

 -  Subject with previously completed routine childhood vaccinations to the best of
 his/her knowledge or his/her parents'/guardians' knowledge.

 -  Female subjects should be of non-childbearing potential.

 Exclusion Criteria:

 -  Previous vaccination against OR history of OR exposure within previous 12 months to
 meningococcal serogroup A, C, W-135 or Y disease.

 -  Administration of a tetanus vaccine within 6 months before study vaccination.

 -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
 human immunodeficiency virus (HIV) infection.

 -  A family history of congenital or hereditary immunodeficiency.

 -  History of any neurologic disorders or seizures.